Loading clinical trials...
Loading clinical trials...
ECMO Braile Biomédica® in COVID-19 Patients Post-market Clinical Trial to Verify the Performance of the ECMO System
Retrospective data collection to evaluate the gas transfer capacity of the Braile Biomédica® OxyPrime® ECMO BRCoating® Membrane Oxygenator in COVID-19 patients during the pandemic.
Multicenter, retrospective, non-comparative, non-randomized study to assess the clinical performance of the OxyPrime® ECMO BRCoating® Membrane Oxygenator in adult patients with COVID-19
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hospital Brasília
Lago Sul, Brasília - DF, Brazil
Start Date
September 14, 2023
Primary Completion Date
January 1, 2024
Completion Date
March 1, 2024
Last Updated
October 17, 2023
30
ESTIMATED participants
Patients underwent cardiorespiratory support
DEVICE
Lead Sponsor
Braile Biomedica Ind. Com. e Repr. Ltda.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06631287